drugset
drugset / Trial / NCT06024174

A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors

NCT06024174 ↗

Phase 1/2 Terminated 5 enrolled Bristol-Myers Squibb
RandomizedSequentialOpen-labelTreatment

Summary

The purpose of this study is to find a safe, tolerable, and efficacious dose of BMS-986466 when given orally, in combination with adagrasib with or without cetuximab in participants with advanced KRAS G12C-mutant non-small cell lung cancer (NSCLC), pancreatic duct adenocarcinoma (PDAC), biliary tract cancer (BTC), or colorectal cancer (CRC).

Timeline

Start
2023-11-09
Primary completion
2024-05-13
Completion
2024-05-13

Drugs

EvaluationDrugModalityDoseRoute
Subject BBP-398 Small molecule — Oral
Subject Cetuximab Monoclonal antibody — —
Background Adagrasib Small molecule — —

Indications

cancer